Market & Competition
Market Size
Heart failure is a major cause of death throughout the world, and is associated with a high rate of morbidity and a lower quality of life than that of patients suffering from any other chronic disease. More than 10 million people suffer from heart failure worldwide. In the US alone, approximately 5 million people suffer from heart failure with more than 500,000 new diagnoses each year. Approximately 10% of heart failure patients, approximately 1 million, are at the end stage of the condition; these patients are considered Class IV heart failure patients per the New York Heart Association guidelines. HeartWare® estimates that each year approximately 100,000 Class IV patients worldwide might benefit from a left ventricular assist device (LVAD), such as the HeartWare® Ventricular Assist Device (HVADTM). The market for LVADs is increasing enormously each year, at a compound annual growth rate of 29.6% for 2010-2015, details in Table 1.
LVADS are used for two primary purposes when treating heart failure patients: bridge-to-transplant therapy (BTT) and destination therapy (DT). BTT refers to the temporary use of an LVAD while awaiting transplantation, whereas DT refers to the permanent or quasi-permanent use of an LVAD. While BTT patients account for the vast majority of the currently treated population, DT is the long-term goal and accounts for the majority of the prospective market. As such, HeartWare®'s primary emphasis is on DT; however, regulatory approval for BTT is an important interim step.
It is estimated that the market for heart failure patients worldwide who do not qualify for transplantation and would require destination therapy is as large 100,000 new patients annually. The ev...
... middle of paper ...
...s based upon the same principles as the MVAD™ but marketed towards pediatrics.
In addition to improving ventricular assist pumps, HeartWare® is also looking to improve its electronic products. It is currently working towards designing a prototype for an implanted controller, through the means of a Transcutaneous Energy Transfer System (TETS). 17 The goal is to successfully implant a battery and controller pack in the patient to eliminate connecting the pump to external electronics. The implanted TETS pack would be recharged via induction across the skin. 17 The TETS platform would eliminate the need for the external driveline, and consequently reduce the risk of infection caused by the driveline. These products in development aim to treat more heart failure patients while also providing more comfort and convenience to those who currently use a HeartWare® pump.
Transcatheter aortic valve replacement or TAVR is the latest technology used principally for the treatment of aortic stenosis, a condition in which one of the major valves of the heart, the aortic valve, becomes tight and stiff, usually as a result of aging (3). Since many patients who need aortic valve replacement for aortic stenosis are too sick to undergo major valve replacement surgery, they are unable to get the treatment they need. With the transcatheter aortic valve, this issue is bypassed because this valve can be implanted in the heart by accessing the patient’s heart through an artery in the groin. The valve can be inserted through a wire that can be pushed to the heart and the old valve is simply pushed to the side when the new valve is implanted. This technology has been in use in the US with Edwards’ Sapiens valve since 2011 and has saved the lives of many patients with aortic stenosis (4). Medtronic’s CoreValve uses similar technology and has won patent fights in Europe and has been in use internationally. However, within U.S., Medtronic has not been...
Ferris H. Hunt S. Destination Vventricular assist devices for heart failure #205. J. Palliat Med. 2009; 12(10):956-957
The aim of this report is to provide an overview of chronic heart failure, examining signs symptoms and treatment related to the case study, and the anatomy and physiology of the heart will be discussed, and the pathophysiology of chronic heart failure.
Takeda A, Taylor SJC, Taylor RS, Khan F, Krum H, Underwood M. (2012). Clinical service organisation for heart failure (Review). Cochrane Database of Systematic Reviews. Issue 9. Art. No.: CD002752. DOI: 10.1002/14651858.CD002752.pub3.
Often, when the heart of an individual fails, the brain, the intestines, and the lungs will usually fail as well. Thus in choosing an individual, they had to find a person who only had cardiac complications and no associated organ failure. They also had to find a patient that was not eligible for a traditional heart transplant.
First of all we need to understand the type of technology this device represents. Is this a sustaining innovation? Or is this a completely new disruptive product? After fully understanding this aspect we can make better decisions regarding the future of the firm and its product. This device offers many benefits that current products do not. As explained earlier, this device is extremely portable, offering emergency rooms the flexibility and convenience they seek to provide patients with the best treatment possible. Likewise, this product will come in at a price point much lower than current echocardiographies, further separ...
The pacemaker system is divided into 2 parts and it is placed underneath the skin below the clavicle. The first part is the pacemaker itself, which is like a computer with batteries. Second part is the electrodes that with the help of the mobile x-ray pictures will be placed correctly. The procedure only takes a little less than a hour. There are different sorts of pacemakers and to make sure it is used most effective there are pacemakers which is helping only where it is needed. The reason for that is so that the heart’s natural way of working is disturbed as little as possible. (Hjärt-Lungfonden, 2008(3) The picture below show the stimulation of the a heart muscle from an electrode that is attached to the part of the pacemaker which contain the batteries.
Standardizing The Hospital Discharge Process for Patients with Heart Failure to Improve the Transition and Lower 30 day Readmission. http://www.cfmc.org/integratingcare/files/Remington%20Report%20Nov%202011%20Standardizing%20the%20Hospital%20Discharge.pdf
...rtinelli, M., Moroni, D., & Salvetti, O. (2010). Decision support in heart failure through processing of electro- and echocardiograms. Artificial Intelligence in Medicine, 2010-10-01, Volume 50, Issue 2, 95-104.
Left-sided heart failure is the most common type of heart failure, and it is a result of left-ventricular dysfunction. This disease poses a significant threat to patients because the primary function of the left side of the heart is to provide sufficient oxygenated blood to satisfy the metabolic demands of the body’s cells. Understanding the main function of this portion of the heart will help with the understanding of other complications associated with this diseased. Left-sided heart failure is usually the result of the loss of heart muscle function, specifically in the left ventricle secondary to coronary artery disease, prolonged hypertension, or myocardial infection (Lewis et al. 2014, 766). The pathophysiology of left-sided heart failure is primary a macroscopic disorder and will be described as such.
My clinical rotation for NURN 236 is unique in that all patients I care for at Union Memorial Hospital in Baltimore, Maryland have a diagnosis of heart failure (HF). HF occurs when the heart is unable to pump adequate blood supply, resulting in insufficient oxygen and nutrients to the tissues of the body (Smeltzer, Bare, Hinkle, and Cheever, 2012). Approximately 670,000 Americans are diagnosed with HF each year and is the most common hospital discharge diagnosis among the elderly (Simpson, 2014). Moreover, according to the Centers for Medicare and Medicaid Services (CMS), HF is the leading cause of 30-day hospital readmission followed by acute myocardial infarction (AMI) and pneumonia (medicare.gov|Hospital Compare, 2013). This information along with my weekly HF patient cohort prompted my curiosity regarding impacts of HF readmissions, factors of HF readmission, and to compare suggested evidence based practice with policies utilized at Union Memorial for reducing the 30-day readmission rate for HF.
It is essential to the human body that the heart pump sufficient nutrient rich blood to the body’s cells, because the body won’t be able to function normally otherwise. When a heart muscle is unable to pump enough blood through to meet the body’s regular demand it is characterized as heart failure. Heart failure can usually be treated through conventional heart therapies and symptom management strategies, however conventional therapies don’t work for all patients with heart failure, this is what is depicted as advanced heart failure or end-stage heart failure. In other words “End stage” heart failure is when the condition becomes so severe that all conventional treatments no longer work, the only treatment that works for end stage heart failure is to have a heart transplantation-surgery to remove a person's diseased heart and replace it with a healthy heart from a deceased donor. However there are two large encompassing problems with this treatment. The first problem is that the patient is subject to shortages in donor organ availability and thus possible further decompensation and potential death while awaiting transplantation. According to the American Heart Association, there are over 500,000 new cases of end-stage heart failure in the United States every year. With only 2200 donor hearts available every year nearly 20-30% of the patients who die while they await a transplant. The second problem with this mode of treatment is that not all patients qualify for heart transplantation. Patients who have another disease in addition to end-stage heart failure do not qualify for heart transplantation. The discrepancy between the clinical need for donor hearts and the total number of hearts available, as well as the lack of treatment o...
“Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood through to meet the body's needs for blood and oxygen” (American Heart Association, 2012, para 3). What this basically means is that the body is functioning in a way that the heart cannot keep up with. Although heart failure can be acute and occur suddenly, it usually develops over time and is a long-term or chronic condition. There are two different types of heart failure, left-sided and right-sided, and they can be caused by other diseases such as diabetes, coronary heart disease, or high blood pressure (National Institutes of Health, 2012). In most cases, both sides of the heart are affected simultaneously.
“60% of people live 10 years after a heart transplant” (www.heartfoundation.org). The process of a heart transplant is crucial because several patients are consulted to see who needs the heart most. The patients provided, which are five of them, each gave a brief biographical and psychological reports. Examining each one carefully, is important, yet difficult to come to a conclusion.Furthermore, each patient demonstrates high hopes in their family of in community. However no medical records have been provided to see if any patient has another organ problem, nor do all the patients have school records.
All companies that are connected with the healthcare system encounter multiple problems that are not being resolved. Queens of Bringing Hearts Together is a company that deals with several heart issues and it is open to the public to provide the best care plans, knowledge and heart transplants at affordable prices for patients. The reason why we decided to construct a company based on heart related issues is because this chronic issue is not taken seriously, as it should be. At the moment it is being stated that, “Heart failure is a progressive and disabling medical condition estimated to affect 5.7 million Americans and consumes an estimated total of $27 billion dollars in annual treatment expenditures” (Gellis 2012). The heart related issues